Dihexa is a small angiotensin IV-derived peptide analog developed as a candidate for cognitive disorders. In preclinical work it is reported to potentiate hepatocyte growth factor (HGF) signaling at the c-Met receptor and to promote synaptogenesis. Human data are essentially absent; it is preclinical/research-only.
Mechanism under study
Proposed to act as an HGF/c-Met system potentiator, augmenting HGF-dependent signaling to drive dendritic-spine formation and synaptogenesis in the hippocampus. Reported to enhance memory in rodent models; the precise molecular binding target remains debated.
Research-reported dosing
No established human dosing. Rodent studies have used oral and injected doses in roughly the microgram-to-low-milligram-per-kilogram range; research-community anecdotes cite low-milligram amounts, but these are unsupported by controlled human data. Preclinical/research-only; not approved.
Dihexa is highly lipophilic and is typically handled dissolved in a solvent vehicle (e.g., DMSO or an oil carrier) rather than bacteriostatic water; it is not a standard water-reconstituted U-100 injectable. Research handling follows its solubility rather than a fixed water mix.
Open this mix in the calculator →Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
Dihexa FAQ
What is Dihexa?
Dihexa is a small angiotensin IV-derived peptide analog developed as a candidate for cognitive disorders. In preclinical work it is reported to potentiate hepatocyte growth factor (HGF) signaling at the c-Met receptor and to promote synaptogenesis. Human data are essentially absent; it is preclinical/research-only.
What is the half-life of Dihexa?
Not well characterized in humans; engineered for improved metabolic stability and blood-brain-barrier penetrance relative to angiotensin IV. Human pharmacokinetics are unpublished.
What is the research-reported dosing for Dihexa?
No established human dosing. Rodent studies have used oral and injected doses in roughly the microgram-to-low-milligram-per-kilogram range; research-community anecdotes cite low-milligram amounts, but these are unsupported by controlled human data. Preclinical/research-only; not approved.
How is Dihexa reconstituted?
Dihexa is highly lipophilic and is typically handled dissolved in a solvent vehicle (e.g., DMSO or an oil carrier) rather than bacteriostatic water; it is not a standard water-reconstituted U-100 injectable. Research handling follows its solubility rather than a fixed water mix.
Is Dihexa FDA-approved?
No — Dihexa is not FDA-approved and is sold for laboratory research use only.
References
Related peptides
Semax
Synthetic ACTH(4-10) fragment analog
A synthetic peptide derived from a fragment of ACTH, developed in Russia and studied for nootropic and neuroprotective effects, typically administered intranasally in research.
Selank
Synthetic heptapeptide (tuftsin analog)
A synthetic analog of the immunomodulatory peptide tuftsin, developed in Russia and studied for anxiolytic (anti-anxiety) and cognitive effects, often administered intranasally in research.
Cerebrolysin
Porcine brain-derived neuropeptide preparation
A neurotrophic preparation of low-molecular-weight peptides and amino acids derived from porcine brain tissue, used in several countries for neurological conditions but not FDA-approved.
P21
Ciliary neurotrophic factor (CNTF)-derived neurogenic peptide (adamantylated small-peptide derivative)
P21 (P021) is a small peptidergic compound derived from an active region of ciliary neurotrophic factor (CNTF), chemically modified (adamantylation) for stability and brain penetration. In preclinical models it is reported to enhance neurogenesis and BDNF signaling and to reduce tau pathology. It is preclinical/research-only.